ARTICLE | Clinical News
Imlygic talimogene laherparepvec regulatory update
January 4, 2016 8:00 AM UTC
The European Commission approved an MAA from Amgen for Imlygic talimogene laherparepvec to treat adults with unresectable melanoma that is regionally or distantly metastatic, with no bone, brain, lung...